COVID-19 Vaccination and the Emergence of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)

In early 2021, as COVID-19 vaccines were being distributed globally, a rare complication emerged involving unusual blood clots in recipients of the AstraZeneca and Johnson & Johnson vaccines. These cases, initially identified in Europe and the U.S., were predominantly linked to the design of the vaccines that used a modified virus to deliver DNA into the body’s cells, unlike the mRNA-based Pfizer and Moderna vaccines.

VITT and Its Characteristics

• Occurrence: VITT was observed in approximately 3 to 10 cases per million vaccinated individuals, varying by age and sex.
• Mechanism: Affected patients produced antibodies against a human protein called platelet factor 4 (PF4), leading to blood clot formation and low platelet counts.
• Immunological Puzzle: Although PF4 is a human protein, vaccines inadvertently led to autoimmune reactions where antibodies targeted PF4.

Understanding Vaccine Functionality

Vaccines act as a "decoy" to prepare the immune system to recognize and combat real infections. COVID-19 vaccines were designed to induce immunity against the coronavirus spike protein without containing the actual virus, by delivering instructions for cells to produce the spike protein briefly.

DNA and mRNA Vaccines

• mRNA Vaccines (Pfizer, Moderna): Utilize mRNA directly, which quickly degrades after prompting protein synthesis in the cell body.
• DNA Vaccines (AstraZeneca, Johnson & Johnson): Employ a genetically modified adenovirus to carry DNA into the nucleus for mRNA production, subsequently leading to spike protein synthesis.

Immune Response and Antibody Diversity

• B Cells: Essential for antibody production, each having unique receptors due to genetic recombination.
• Antibody Development: Involves an iterative cycle of mutation and selection enhancing binding specificity to antigens.
• VITT Antibodies: Contrary to typical antibody uniqueness, antibodies from VITT patients across different regions were molecularly similar.

Molecular Insights into VITT

• Research revealed that nearly all affected patients shared similar genetic variations in antibody genes (IGLV3-21*02 or *03).
• Specific mutations altered electrical charges on antibodies, enhancing their binding to PF4 and activating platelets.

Adenovirus Vector Vaccines and Protein VII

• The adenovirus used in these vaccines contains protein VII, resembling parts of PF4, misleading the immune system to target PF4.
• Antibodies initially aimed at adenovirus components were inadvertently refined to attack PF4 due to genetic predispositions.

Impact and Future Directions

The study provides clarity on the molecular causes of VITT, highlighting protein VII as the trigger, and offers insights for future vaccine design to enhance safety in adenoviral vector vaccines.